Vigil Neuroscience reports data from Phase 1 trial on VG-3927

Vigil Neuroscience (VIGL) announced positive data from its completed Phase 1 clinical trial evaluating VG-3927 for the potential treatment of AD. Collectively, the safety, tolerability, pharmacokinetic, PK, and pharmacodynamic, PD, profile supports the advancement of VG-3927 into a Phase 2 clinical trial as a potential once-daily oral therapy for AD. Safety, tolerability, pharmacokinetic, and pharmacodynamic profile supports continued development of VG-3927 as potential once-daily oral therapy for Alzheimer’s disease; Robust and dose-dependent reductions of sTREM2 were achieved demonstrating sustained functional target engagement; Company plans to advance VG-3927 into a Phase 2 trial in the third quarter of 2025; Selects 25mg QD oral as a dose that fully engages desired pharmacology